Abeona eligible for milestones and royalties after FAYUVI approval
Abeona says Ultragenyx received FDA approval for FAYUVI (UX111), originally developed by Abeona as ABO-102, making Abeona eligible for commercial milestones and royalties under its 2022 out-licensing deal.
Story updates
11:32:38 AM UTC
SquawkNews
Abeona said Ultragenyx won FDA approval for FAYUVI (UX111), originally developed by Abeona as ABO-102, making Abeona eligible for commercial milestones and royalties under its 2022 out-licensing deal.Material DetailsContext by AI AnalystThis is late-stage validation of a partnered asset that Abeona…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.